Cagatay Arslan
Overview
Explore the profile of Cagatay Arslan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bolek H, Kuzu O, Camoz E, Sim S, Sekmek S, Karakas H, et al.
Cancer Commun (Lond)
. 2025 Feb;
PMID: 39927571
No abstract available.
2.
Bolek H, Yazgan S, Ceylan F, Esteban-Villarrubia J, Arslan C, Kus T, et al.
Eur J Cancer
. 2025 Jan;
217:115226.
PMID: 39813762
Background: Cabazitaxel and Lu-PSMA-617 have been shown to improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and androgen receptor pathway inhibitors (ARPI). we aimed...
3.
Bolek H, Kuzu O, Camoz E, Sim S, Sekmek S, Karakas H, et al.
Clin Transl Oncol
. 2025 Jan;
PMID: 39812937
Purpose: Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role...
4.
Degerli E, Arslan C, Selcukbiricik F, Olmez O, Erdem D, Hamdard J, et al.
Medicina (Kaunas)
. 2025 Jan;
60(12.
PMID: 39768982
: A high baseline neutrophil-to-lymphocyte ratio (NLR) is a poor prognostic factor in various cancers. However, its predictive role in metastatic bladder cancer (mBC) treated with immunotherapy is unclear. In...
5.
Bolek H, Sertesen E, Kuzu O, Tural D, Sim S, Sendur M, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102282.
PMID: 39709686
Introduction: Despite the rapid evolution in management of metastatic renal cell carcinoma (mRCC) over the past decade, challenges remain in accessing new therapies in some parts of the world. Despite...
6.
Tural D, Arslan C, Selcukbiricik F, Olmez O, Akar E, Erman M, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102228.
PMID: 39461025
Background: In this study, we reported the real-life results of data from impaired renal patients with urothelial carcinoma who were treated with ICTs. Methods: The patients were categorized into 3...
7.
Verlingue L, Italiano A, Prenen H, Alia E, Tosi D, Perets R, et al.
EBioMedicine
. 2024 Oct;
109:105374.
PMID: 39395231
Background: Simlukafusp alfa (FAP-IL2v) is an immune cytokine engineered to selectively promote immune responses in the tumour microenvironment. We evaluated the antitumour activity and safety of FAP-IL2v plus atezolizumab in...
8.
Clarke N, Armstrong A, Oya M, Shore N, Procopio G, Guedes J, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39384451
Background And Objective: In PROpel (NCT03732820), olaparib + abiraterone resulted in a statistically significant radiographic progression-free survival (rPFS) benefit and numerically prolonged overall survival (OS) versus placebo + abiraterone in...
9.
Yildirim H, Bayram E, Chalabiyev E, Majidova N, Avci T, Guzel H, et al.
J Chemother
. 2024 Sep;
:1-12.
PMID: 39257075
Non-clear cell renal cell carcinoma (non-ccRCC) is a highly heterogeneous disease group, accounting for approximately 25% of all RCC cases. Due to its rarity and especially heterogeneity, phase III trial...
10.
Bolek H, Arslan C, Basaran M, Cicin I, Ozguroglu M, Tural D, et al.
JCO Glob Oncol
. 2024 Aug;
10():e2400201.
PMID: 39208383
Purpose: Durable complete response rates for metastatic renal cell carcinoma (mRCC) and metastatic bladder cancer (mBC) are low despite new therapy. Palliative care focuses on life extension and quality of...